Pediatric Cardiology

, Volume 3, Issue 3, pp 265–272 | Cite as

Anthracycline cardiomyopathy

  • Nathan L. Kobrinsky
  • Norma K. C. Ramsay
  • William Krivit
Article

Summary

Life-threatening irreversible cardiomyopathy is a major complication of anthracycline therapy, particularly in the pediatric population. The pediatric cardiologist, in concert with the primary oncologist, should therefore play a major role in the care of patients receiving these agents and in clinical trials involving their use. Many risk factors and their relationships to drug pharmacokinetics, mechanisms of action, and toxicity have been identified. These data provide a rational basis for present-day recommendations regarding anthracycline administration and dosage scheduling. They furthermore provide potential avenues for clinical investigation aimed at improving the therapeutic index of these agents: α-tocopherol, cytochrome Q10, and other free radical scavengers may decrease the deleterious effects of free radical generation on the myocardium without apparent interference with tumoricidal effect. The cardiac glycosides may decrease cardiac toxicity by specific myocardial exclusion. Anthracycline analogs have been designed to specifically inhibit myocardial binding and/or free radical generation. Clinical trials involving these agents are difficult to interpret because of variability in front end risk factors and dosage schedules in the study population. Furthermore, the relatively low (5 to 10%) incidence of affected patients implies the need for large numbers to demonstrate a statistically significant benefit. Pediatric protocols addressing these issues are urgently needed. Guidelines for present-day management and future studies are outlined.

Key words

Anthracycline Cardiomyopathy Free radical Anthracycline analogs 

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Alexander I, Dainiak N, Berger H, Goldman L, Johnstone D, Reduto L, Duffy T, Schwartz T, Gottschalk A, Zaret BL: Serial assessment of doxorubicin cardiotoxicity with quantitative radionucleotide angiocardiography.N Engl J Med 300:278–283, 1979Google Scholar
  2. 2.
    Anderson B, Beran M: Leukemic cell versus plasma levels of daunorubicin and daunorubicinol after infusion of daunorubicin as free drug or the DNA complex.Cancer Chemother Pharmacol 4:205–207, 1980Google Scholar
  3. 3.
    Arcamone F, Franceschi GF, Penco S, Selva A: Adriamycin, a novel antitumor antibiotic.Tetrahedron Lett 13:1007–1010, 1969Google Scholar
  4. 4.
    Arena E, D'Alessandro N, Dusonchet L, Gebbia N, Gerbas, E: Analysis of the pharmacokinetic characteristics, pharmacological and chemotherapeutic activity of 14-hydroxy-daunomycin (Adriamycin), a new drug endowed with an antitumor activity.Arzneim Forsch 21:1258–1263, 1971Google Scholar
  5. 5.
    Bachur NR: Anthracycline antibiotic pharmacology and metabolism.Cancer Treat Rep 63:817–820, 1979Google Scholar
  6. 6.
    Bachur NR, Benjamin RS, Hall TC: Proceedings of the Fifth New Drug Seminar on Adriamycin and the Adriamycin New Drug Seminar.Cancer Chemother Rep, Part 3 6:83–397, 1975Google Scholar
  7. 7.
    Bachur NR, Gordon SL, Gee MV: Anthracycline antibiotic augmentation of microsomal electron transport and free radical formation.Molec Pharmacol 13:901–910, 1977Google Scholar
  8. 8.
    Bachur NR, Gordon SL, Gee MV: A general mechanism for microsomal activation of quinone anticancer agents to free radicals.Cancer Res 38:1745–1750, 1978Google Scholar
  9. 9.
    Barlogie B, Drewinko B, Johnston DA, Freireich EJ: The effect of Adriamycin on the cell cycle traverse of a human lymphoid cell line.Cancer Res 36:1975–1979, 1976Google Scholar
  10. 10.
    Benjamin RS, Riggs CE, Bachur NR: Pharmacokinetics and metabolism of Adriamycin in man.Clin Pharmacol Ther 14:592–600, 1973Google Scholar
  11. 11.
    Benjamin RS, Riggs CE, Bachur NR: Plasma pharmacokinetics of Adriamycin and its metabolites in humans with normal hepatic and renal function.Cancer Res 37:1416–1420, 1977Google Scholar
  12. 12.
    Benjamin RS, Riggs CE, Serpick AA, Bachur NR: Human metabolism of Adriamycin. (Abstr).AACR 15:76, 1974Google Scholar
  13. 13.
    Benjamin RS, Wiernik PH, Bachur NR: Adriamycin chemotherapy—efficacy, safety, and pharmacologic basis of an intermittent single high-dose schedule.Cancer 33:19–27, 1974Google Scholar
  14. 14.
    Bern MM, McDermott W, Cady B, Oberfield RA, Trey C, Clouse ME, Tullis JL, Parker LM: Intraarterial hepatic infusion and intravenous Adriamycin for treatment of hepatocellular carcinoma. A clinical and pharmacological report.Cancer 42:399–405, 1978Google Scholar
  15. 15.
    Bhanot P, Cushing B, Philippart A, Das L, Farooki Z: Hepatic irradiation and Adriamycin cardiotoxicity.J Ped 95:561–563, 1979Google Scholar
  16. 16.
    Biancaniello T, Meyer RA, Wong KY, Sager C, Kaplan S: Doxorubicin cardiotoxicity in children.J Ped 97:45–50, 1980Google Scholar
  17. 17.
    Bonadonna G, Monfardini S, Delena M, Fossati-Bellani F, Baretta G: Clinical trials with Adriamycin—results of a three year study. In Carter SK, DiMarco A, Ghione M, Krakoff IH, Mathe G. eds.International Symposium on Adriamycin. New York: Springer-Verlag, 1972, pp. 143-152Google Scholar
  18. 18.
    Bristow MR, Billingham ME, Mason JW, Daniels JR: Clinical spectrum of anthracycline cardiotoxicity.Cancer Treat Rep 62:873–879, 1978Google Scholar
  19. 19.
    Bristow MR, Mason JW, Billingham ME, Daniels JR: Doxorubicin cardiomyopathy: Evaluation by phonocardiography, endomyocardial biopsy and cardiac catheterization.Ann Int Med 88:168, 1978Google Scholar
  20. 20.
    Carter SK, DiMarco A, Ghione M, Krakoff IH, Mathe G: eds:International Symposium on Adriamycin, New York: Springer-Verlag, 1972Google Scholar
  21. 21.
    Chlebowski RT, Paroly WS, Pugh RP, Hueser J, Jacobs EM, Pajak TF, Bateman JR: Adriamycin given as a weekly schedule without a loading course: Clinically effective with reduced incidence of cardiotoxicity.Cancer Treat Rep 64:47–51, 1980Google Scholar
  22. 22.
    Cortes EP, Gupta M, Chau C, Amin VC, Folkers K: Adriamycin cardiotoxicity: Early detection by systolic time interval and possible prevention by coenzyme Q10.Cancer Treat Rep 62:887–891, 1978Google Scholar
  23. 23.
    D'Angio GJ, Raney RB, Schnaryer L, Bishop HC, Chatten J, Littman P: Management of children with sacrococcygeal teratoma (ST).ASCO (Abstr C-206)21:386, 1980Google Scholar
  24. 24.
    Davis HL, Davis TE: Daunorubicin and Adriamycin in cancer treatment: An analysis of their roles and limitations.Cancer Treat Rep 63:809–815, 1979Google Scholar
  25. 25.
    DiMarco A, Gaetani M, Orezzi PO, Scarpinato BM, Silvestrini R, Soldati M, Dasdia T, Vanentini L: Daunomycin, a new antibiotic of the rhodomycin group.Nature 201:706–707, 1964Google Scholar
  26. 26.
    DiMarco A, Zunino F, Silvestrini R, Ganbarucii C, Gambetta RA: Interaction of some daunomycin derivatives with deoxyribonucleic acid and their biological activity.Biochem Pharmacol 20:1323–1328, 1971Google Scholar
  27. 27.
    Doroshow JH, Locke GY, Myers CE: The prevention of doxorubicin cardiac toxicity by N-acetyl-L-cysteine.AACR (Abstr)253, 1979Google Scholar
  28. 28.
    Evans WE, Crom WR, Yee GC, Green AA, Hayes FA, Pratt CB, Avery L: Adriamycin pharmacokinetics in children.AACR 21 (Abstr 705): 176, 1980Google Scholar
  29. 29.
    Ferrans VF: Overview of cardiac pathology in relation to anthracycline cardiotoxicity.Cancer Treat Rep 62:955–961, 1978Google Scholar
  30. 30.
    Gilladoga AC, Manuel C, Tan CT, Wollner N, Sternberg SS, Murphy ML: The cardiotoxicity of Adriamycin and daunomycin in children.Cancer 37 (2 suppl):1070–1078, 1976Google Scholar
  31. 31.
    Goodman J, Hochstein P: Generation of free radicals and lipid peroxidation by redox cycling of Adriamycin and Daunomycin®.Biochem Biophys Res Commun 77:797–803, 1977Google Scholar
  32. 32.
    Halazun JR, Wagner HR, Gaeta JR, Sinks LF: Daunorubicin cardiotoxicity in children with acute lymphocytic leukemia.Cancer 33:545–554, 1974Google Scholar
  33. 33.
    Handa K, Sato S: Generation of free radicals of quinone group-containing anti cancer chemicals in NADPH-microsome systems as evidence by initiation of sulfite oxidation.Gann 60:43–47, 1975Google Scholar
  34. 34.
    Handa K, Sato S: Stimulation of NADPH oxidation by quinone group containing anti cancer chemicals.Gann 67:523, 1976Google Scholar
  35. 35.
    Israel M, Modest E, Frei E: N-trifluoracetyl Adriamycin-14-valerate (AD 32), an analog with greater experimental anti-tumor activity and less toxicity than Adriamycin.Cancer Res 35:1365–1368, 1975Google Scholar
  36. 36.
    Iwamoto Y, Hansen IL, Porte TH, Fokers K: Inhibition of co-enzyme Q10-enzymes, succinoxidase and NADH-oxidase by Adriamycin and other quinones having anti-tumor activity.Biochem Res Commun 58:633–638, 1974Google Scholar
  37. 37.
    Jaenke RS, Deprez-De Campeneere D, Trouet A: Cardiotoxicity and comparative pharmacokinetics of six anthracyclines in the rabbit.Cancer Res 40:3530–3536, 1980Google Scholar
  38. 38.
    Kobrinsky NL, Robison LL, Nesbit ME Jr: Acute nonlymphocytic leukemia.Ped Cl NA 27:345–360, 1980Google Scholar
  39. 39.
    Krivit W: Adriamycin cardiotoxicity amelioration by α-tocopherol.Am J Ped Hematol/Oncol 1:151–153, 1979Google Scholar
  40. 40.
    Lee Y-TN, Chan KK, Harris PA, Cohen JL: Distribution of Adriamycin in cancer patients. Tissue uptakes, plasma concentration after IV and hepatic IA administration.Cancer 45:2231–2239, 1980Google Scholar
  41. 41.
    Merski J, Daskal Y, Busch H: Comparison of Adriamycin-induced nucleolar segregation in skeletal muscle, cardiac muscle and liver cells.Cancer Treat Rep 62:771–778, 1978Google Scholar
  42. 42.
    Michelsen RB, Lin PS, Wallach DFH: Interaction of Adriamycin with human red blood cells: A biochemical and morphological study.J Molec Med 2:33–40, 1977Google Scholar
  43. 43.
    Middleman E, Luu J, Frei E: Clinical trials with Adriamycin.Cancer 28:844–850, 1970Google Scholar
  44. 44.
    Mosojczvk AD, Ruymann FB, Mease AD, Bernier RD: Anthracycline cardiomyopathy in children: Report of two cases.Cancer 44:1582–1587, 1979Google Scholar
  45. 45.
    Myers CE, McGuire WP: Proceedings of the conference on noninvasive and invasive prospective monitoring for anthracycline cardiotoxicity.Cancer Treat Rep 62:885–982, 1978Google Scholar
  46. 46.
    Myers CE, McGuire WP, Liss RH, Ifrim I, Grotzinger K, Young RC: Adriamycin: The role of lipid peroxidation in cardiac toxicity and tumor response.Science 197:165–167, 1977Google Scholar
  47. 47.
    Nevstad N: Sister chromatid exchanges and chromosomal aberrations induced in human lymphocytes by the cytostatic drug Adriamycin in vivo and in vitro.Mutation Res 57:253, 1977Google Scholar
  48. 48.
    Olson HM, Shannon CF: Alterations of lactate dehydrogenase isoenzymes with subacute Adriamycin toxicity.Cancer Treat Rep 63:2057–2059, 1979Google Scholar
  49. 49.
    Phillips FS, Gilladoga A, Marquardt H, Stenberg SS, Vidal P: Some observations on the cardiotoxicity of Adriamycin (NSC-123127).Cancer Chem Rep (Part 3)6:177–181, 1975Google Scholar
  50. 50.
    Praga C, Baretta G, Vigo PL, Lenaz GR, Pollini C, Bonadonna G, Canetta R, Castella R, Villa E, Gallagher CG, von Melchner H, Hayat M, Ribaud P, De Wasch G, Mattsson W, Heinz R, Waldnar R, Kolaric K. Buehner R, Bokkel-Huyninck WT, Pererodahikova NI, Mauziuk LA, Senn SHJ, Mayr AC: Adriamycin cardiotoxicity: A survey of 1273 patients.Cancer Treat Rep 63:827–834, 1979Google Scholar
  51. 51.
    Pratt CB, Ransom JL, Evans WE: Age-related Adriamycin cardiotoxicity in children.Cancer Treat Rep 62:1481–1485, 1978Google Scholar
  52. 52.
    Proceedings of the NCI-EORTC Symposium on New Drugs in Cancer Therapy.Cancer Treat Rep 63:807–936, 1979Google Scholar
  53. 53.
    Rahman A, Kessler A, More N, Sikic B, Rowden G, Woolley P, Schein PS: Liposomal protection of Adriamycin-induced cardiotoxicity in mice.Cancer Res 40:1532–1537, 1980Google Scholar
  54. 54.
    Ramos A, Meyer RA, Korfhagen J, Wong KY, Kaplan S: Echocardiographic evaluation of Adriamycin cardiotoxicity in children.Cancer Treat Rep 60:1281–1284, 1976Google Scholar
  55. 55.
    Ritchie JL, Singer JW, Thorning D, Sorensen SG, Hamilton GW: Anthracycline cardiotoxicity: Clinical and pathologic outcomes assessed by radionuclide ejection fraction.Cancer 46:1109–1116, 1980Google Scholar
  56. 56.
    Rozencweig M, DeSloover C, VonHoff DD, Tagnon HJ, Muggia FM: NCI-EORTC Symposium on New Drugs in Cancer Therapy. Introduction: Anthracycline derivatives in New Drug Development Programs.Cancer Treat Rep 63:807–808, 1979Google Scholar
  57. 57.
    Somberg J, Cagin N, Bovnous H, Levitt HB: The effect of digoxin on the binding of Adriamycin to cat heart muscle (letter).Brit J Cancer 35:123, 1977Google Scholar
  58. 58.
    Thayer WS: Adriamycin stimulated superoxide formation in submitochondrial particles.Chem Biol Interact 19:265–278, 1977Google Scholar
  59. 59.
    Trouet A, Sokol G: Clinical studies with daunorubicin-DNA and Adriamycin-DNA complexes: A Review.Cancer Treat Rep 63:895–898, 1979Google Scholar
  60. 60.
    Ulmer HE, Ludwig R, Geiger H: Assessment of Adriamycin cardiotoxicity in children by systolic time intervals.Eur J Pediatr 131:21–31, 1979Google Scholar
  61. 61.
    Villani F, Piccinioui F, Merelli P, Favalli L: Influence of Adriamycin on calcium exchangeability in cardiac muscle and its modification by ouabain.Biochem Pharmacol 27:985–987, 1978Google Scholar
  62. 62.
    VonHoff DD, Layard MW, Basa P, Davis HL Jr, Rozencweig M, Muggia FM: Analysis of risk factors for development of Adriamycin induced congestive heart failure (CHF).AACR (Abst 216)19:54, 1978Google Scholar
  63. 63.
    VonHoff DD, Layard MW, Basa P, Davis HL Jr, Rozencweig M, Muggia FM: Risk factors for doxorubicin-induced congestive heart failure.Ann Int Med 91:710–717, 1979Google Scholar
  64. 64.
    VonHoff DD, Rozencweig M, Layard MW, Slavik, Muggia FM: Daunomycin-induced cardiotoxicity in children and adults: A review of 110 cases.Am J Med 62:200–208, 1977Google Scholar
  65. 65.
    Weiss AJ, Mette GE, Fletcher WS, Wilson WL, Grage TB, Raimirez G: Studies on Adriamycin using a weekly regimen demonstrating its clinical effectiveness and lack of cardiac toxicity.Cancer Treat Rep 60:813–822, 1976Google Scholar
  66. 66.
    Wortmen JE, Lucas VS, Pharm BS, Schuster E, Thiele D, Logue GL: Sudden death during doxorubicin administration.Cancer 44:1588–1591, 1979Google Scholar
  67. 67.
    Wright SD, Bachur NR: Alterations in Adriamycin efficacy by phenobarbital.Cancer Res 36:3803, 1976A0946011 00013 CS-SPJRNPDF [HEADSUP]Google Scholar

Copyright information

© Springer-Verlag New York Inc. 1982

Authors and Affiliations

  • Nathan L. Kobrinsky
    • 1
  • Norma K. C. Ramsay
    • 1
  • William Krivit
    • 1
  1. 1.Department of Pediatrics, Division of Hematology-OncologyUniversity of MinnesotaMinneapolis

Personalised recommendations